probenecid has been researched along with Phlegmon in 5 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A once-daily regimen of cefazolin (2 g intravenously [iv]) plus probenecid (1 g by mouth) was compared with a once-daily regimen of ceftriaxone (1 g iv) plus oral placebo in a randomized, double-blind equivalence trial of home-based therapy for moderate-to-severe cellulitis in adults." | 9.10 | Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. ( Athan, E; Chambers, F; Gibson, K; Grayson, ML; McDonald, M; Munckhof, WJ; Paull, P, 2002) |
| "Once-daily intravenous cefazolin with probenecid is used commonly to treat cellulitis." | 7.77 | Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid. ( Bader, MS; Hawboldt, J; Twells, L, 2011) |
| "A once-daily regimen of cefazolin (2 g intravenously [iv]) plus probenecid (1 g by mouth) was compared with a once-daily regimen of ceftriaxone (1 g iv) plus oral placebo in a randomized, double-blind equivalence trial of home-based therapy for moderate-to-severe cellulitis in adults." | 5.10 | Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. ( Athan, E; Chambers, F; Gibson, K; Grayson, ML; McDonald, M; Munckhof, WJ; Paull, P, 2002) |
| "Once-daily intravenous cefazolin with probenecid is used commonly to treat cellulitis." | 3.77 | Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid. ( Bader, MS; Hawboldt, J; Twells, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bader, MS | 1 |
| Twells, L | 1 |
| Hawboldt, J | 1 |
| Edwards, J | 1 |
| Green, P | 1 |
| Haase, D | 1 |
| Khangura, S | 1 |
| Wallace, J | 1 |
| Kissoon, N | 1 |
| Kodeeswaran, T | 1 |
| Grayson, ML | 1 |
| McDonald, M | 1 |
| Gibson, K | 1 |
| Athan, E | 1 |
| Munckhof, WJ | 1 |
| Paull, P | 1 |
| Chambers, F | 1 |
| Bodey, GP | 1 |
| Rodriguez, V | 1 |
| Luce, JK | 1 |
1 trial available for probenecid and Phlegmon
| Article | Year |
|---|---|
Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cefazolin; Ceftriaxone; Cellulitis | 2002 |
4 other studies available for probenecid and Phlegmon
| Article | Year |
|---|---|
Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid.
Topics: Administration, Oral; Anti-Bacterial Agents; Cefazolin; Cellulitis; Chi-Square Distribution; Drug Th | 2011 |
A blistering disease: bullous erysipelas.
Topics: Anti-Bacterial Agents; Blister; Cefazolin; Cellulitis; Diabetes Mellitus, Type 2; Erysipelas; Humans | 2006 |
Management of cellulitis in a pediatric emergency department.
Topics: Academic Medical Centers; Adjuvants, Pharmaceutic; Administration, Oral; Adolescent; Anti-Bacterial | 2007 |
Carbenicillin therapy of gram-negative bacilli infections.
Topics: Adolescent; Cellulitis; Child; Enterobacteriaceae Infections; Escherichia coli Infections; Humans; K | 1969 |